(Q40055904)

16 September 2017

title

Engineering of a stable retroviral gene delivery vector by directed evolution (English)

1 reference

16 September 2017

0 references

Halong N Vu

1

1 reference

16 September 2017

Joshua D Ramsey

series ordinal

2

1 reference

16 September 2017

Daniel W Pack

series ordinal

3

1 reference

16 September 2017

publication date

6 November 2007

1 reference

16 September 2017

1 reference

16 September 2017

volume

16

1 reference

16 September 2017

issue

2

1 reference

16 September 2017

page(s)

308-314

1 reference

Gene therapy: trials and tribulations

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Progress and problems with the use of viral vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Ligand-directed targeting of genes to the site of disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Large-scale processing of recombinant retroviruses for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

State-of-the-art of the production of retroviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Breeding of retroviruses by DNA shuffling for improved stability and processing yields

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Kinetics of retrovirus production and decay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

The nature of the association between the murine leukemia virus envelope proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

In vitro cell-free conversion of noninfectious Moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Macromolecular requirements for abrogation of Fv-1 restriction by murine leukemia viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Genome shuffling leads to rapid phenotypic improvement in bacteria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Determination of Infectious Retrovirus Concentration from Colony-Forming Assay with Quantitative Analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Structural and biochemical studies of retroviral proteases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Structural alignment of retroviral protease sequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

A structural model for the retroviral proteases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

The structural stability of the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

A transient three-plasmid expression system for the production of high titer retroviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300350

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300350

1 reference

16 September 2017

1 reference